Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 17:8:87-95.
doi: 10.33393/grhta.2021.2238. eCollection 2021 Jan-Dec.

Analisi di Budget Impact di ponatinib per il management di pazienti affetti da leucemia mieloide cronica

[Article in Italian]
Michele Basile  1   2 , Filippo Rumi  1   2 , Americo Cicchetti  1   2
Affiliations

Analisi di Budget Impact di ponatinib per il management di pazienti affetti da leucemia mieloide cronica

[Article in Italian]
Michele Basile et al. Glob Reg Health Technol Assess. .

Abstract

Background:: The current clinical practice for patients affected by chronic myeloid leukemia (CML) is based on the evaluation of second generation alternatives following therapeutic failure that leads to a lengthening of patients’ management times and a consequent negative impact in terms of quality of life.

Objective:: To determine the economic absorption of resources associated to the management of patients with CML in a scenario in which an early recourse to ponatinib is considered as compared with a scenario based on the current Italian clinical practice characterized by a cyclical recourse to the available therapies.

Methods:: A Budget Impact model was developed to compare the resources absorbed in the scenarios under assessment considering a 3-year time horizon and the perspective of the Italian National Health Service. Results are expressed in terms of differential resources absorbed in the alternative scenarios.

Results:: The increase in the recourse to ponatinib allowed a saving of resources for the Italian NHS over the 3-year time horizon of –€ 1,979,322 (€ 825,104,350 vs € 823,125,028). The parameter affecting the most of the results achieved in the base-case is the monthly cost of bosutinib used as a third-line treatment.

Conclusions:: The increase in the recourse to ponatinib in patients affected by CML that failed to respond to a previous pharmacological therapy resulted to be associated to a lower level of resources’ absorption in the Italian NHS allowing to re-allocate health founds to other fields of the care sector ensuring greater sustainability of the system.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None of the authors has any potential conflict of interest related to this manuscript.

Figures

Fig. 1 -
Fig. 1 -
Analisi differenziale dello scenario con (to be) e senza (as is) un ricorso anticipato a ponatinib.
Fig. 2 -
Fig. 2 -
Analisi di sensibilità univariata.
See this image and copyright information in PMC

References

    1. Tura S, Baccarani M, Zaccaria A. Chronic myeloid leukemia. Haematologica. 1986;71(3):169–176. PubMed - PubMed
    1. Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. Hematology (Am Soc Hematol Educ Program). 2003;2003(1):132–152. doi: 10.1182/asheducation-2003.1.132. PubMed - DOI - PubMed
    1. Cortes JE, Talpaz M, Kantarjian H. Chronic myelogenous leukemia: a review. Am J Med. 1996;100(5):555–570. doi: 10.1016/S0002-9343(96)00061-7. PubMed - DOI - PubMed
    1. Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol. 2003;40(1):79–86. doi: 10.1016/S0037-1963(03)70045-6. PubMed - DOI - PubMed
    1. Deininger M, O’Brien SG, Guilhot F et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. ASH Annual Meeting Abstracts. 2009;114:1126. Online

LinkOut - more resources